Literature DB >> 30068880

Development of an Alcohol Dilution-Lyophilization Method for Preparing Lipid Nanoparticles Containing Encapsulated siRNA.

Daiki Shirane1, Hiroki Tanaka1, Yuta Nakai2, Hiroki Yoshioka2, Hidetaka Akita1.   

Abstract

Systems for delivering nucleic acids are now fundamental technologies for realizing personalized medicine. Among the various nucleic acid delivery systems that are currently available, lipid-nanoparticles (LNPs) that contain short interfering RNA (siRNA) have been extensively investigated for clinical applications. LNPs are generally prepared by an alcohol dilution method. In this method, it is necessary to remove the alcohol and then concentrate the LNP sample before they can be used. In this study, we report on the development of an "alcohol dilution-lyophilization method" for preparing siRNA-encapsulating LNPs. This method involves the use of a freeze-drying (lyophilization) method to remove the residual alcohol and to simultaneously concentrate the preparation. At first, the compositions of cryoprotectants and polyethylene glycol (PEG)-lipids that were used were optimized from the point of view of particle stabilization. A combination of sucrose and 1-(monomethoxy polyethyleneglycol5000)-2,3-dimyristoylglycerol (DMG-PEG5000) was found to have the most efficient cryoprotective activity for the LNPs. The knockdown efficiency of the LNP prepared by the alcohol dilution-lyophilization method was comparable to that of an LNP prepared by the conventional ultrafiltration method.

Entities:  

Keywords:  drug delivery system; freeze drying; lipid nano particle; short interfering RNA (siRNA)

Mesh:

Substances:

Year:  2018        PMID: 30068880     DOI: 10.1248/bpb.b18-00208

Source DB:  PubMed          Journal:  Biol Pharm Bull        ISSN: 0918-6158            Impact factor:   2.233


  1 in total

Review 1.  mRNA-lipid nanoparticle COVID-19 vaccines: Structure and stability.

Authors:  Linde Schoenmaker; Dominik Witzigmann; Jayesh A Kulkarni; Rein Verbeke; Gideon Kersten; Wim Jiskoot; Daan J A Crommelin
Journal:  Int J Pharm       Date:  2021-04-09       Impact factor: 6.510

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.